Innovative treatments

for Solid Cancers

by selective targeted

protein degradation

World leading team with globally-recognised scientific foundations

Via Giovanni de Medici 61/b

20811 Cesano Maderno (MB) - Italy

P.iva 13069630963

REA  MB 2701987

info@thera65.com

Registered Innovative Startups

Innovative treatments

for Solid Cancers

by selective targeted

protein degradation

© 2024 - Contributi

Advanced research in biotech-field developing innovative personalized therapies

for hard-to-treat solid cancers.

Vision

To transform the paradigm of oncology treatments through innovation and personalization. We aim to provide cutting-edge diagnostic and therapeutic solutions tailored to the individual needs of patients, improving their quality of life.

Mission

To be a leader in identifying and developing personalized innovative diagnostic solutions and treatments in oncology that maximize therapeutic efficacy and minimize side effects. We are committed to conducting innovative research to understand the specific molecular characteristics of solid tumors, in order to provide precise diagnoses and personalized therapies.

Philosophy

Our claim embodies the essence of our philosophy.

We are driven by the desire to make a significant impact in people's lives, especially cancer patients.

Our research is rooted in trust in science and the belief that innovation can open new horizons in the fight against cancer.

We don't settle for traditional approaches we embrace the future of personalized therapies, offering renewed hope to those facing this challenge

We want every individual to feel accompanied, supported, and inspired along their journey, so they can truly "Feel life better".

Technology

Our technology is based on the groundbreaking discovery of the new biomarker p65BTK

an oncogenic protein expressed in various

solid cancer

We are developing a personalized approach to address the unmet clinical need for more effective therapies.

Approach

BIONSEEK’s strategy involves developing an Nanoparticle-carried Aptamer-based PROTAC

to specifically degrade p65BTK

with the aim of re-sensitizing to treatment resistant cancers such as Ovarian carcinomas, Colorectal cancer and NSCLCs.

Degrader vs inhibitor

Degraders are more effective than inhibitors

Protein kinase inhibitors have been used in cancer treatment for more than two decades. They work by blocking the action of protein kinases, enzymes that control the function of proteins and can lead to unregulated cell growth if they become mutated.
Although these treatments can work well, there is a risk of the cancer becoming resistant to them. This is because inhibitors obstruct cancer-related proteins rather than destroying them, and the tumour cells can sometimes reactivate them.
In addition, when some protein kinases are blocked by inhibitors, the cell compensates by using other kinases to perform the same actions.
Getting rid of the proteins entirely through protein degradation removes these risks.
 

Team

World leading team with globally-recognised scientific foundations

Emanuela Grassilli

Maria Grazia Cerrito

Sandra Misale

Angelo Morini

Co-founder & CSO 

Associate Professor of General Pathology at Link Campus University

Co-founder & COO 

Staff Scientist and Adjunct Professor of Pathology and Molecular Medicine at the University of Milano-Bicocca
 

Co-founder & CSB Assistant professor at Johns Hopkins University School of Medicine - USA
 

Co-founder & CEO
Entrepreneur, Second time Founder, and Business Angel

 

Scientific Advisory Board.....the Scientific Advisory Board is still being completed

Cornelia Brunner

Andrea Testa

Pier Francesco Ferrucci

Director at Department of Oncology
Gruppo Multimedica - ITA
 

Adjunct professor at Ulm University Medical Center; Head of the oncology research laboratory

TRIMTECH Therapeutics (Senior Director Chemistry) PROTAC expert

Rita Garuti

Pier Paolo Claudio

Professor of Pharmacology and Toxicology at the University of Mississippi Cancer Center & Research Institute - USA

Senior Director of Quality Control and Analytical Science at BlueRock Therapeutics, Cambridge, Massachusetts - USA